Filter announcements
Loading...
Strides Pharma Science Ltd is in the business of development and manufacturing of pharmaceutical products.The company's pharmaceutical products are sold in over 100 countries.The company has always followed an inorganic growth strategy over the years that resulted in foray into new markets, addition of new business segments, therapy segments and manufacturing infrastructure.
Strides Pharma completed its majority stake sale in Pivot Path to an Ascent Capital-led consortium for ₹100 Cr. The company received ₹75 Cr, with ₹25 Cr due in a year. Pivot Path is now an Associate Company.
Strides Pharma is divesting a majority stake in its subsidiary, Pivot Path, to a consortium led by Ascent Capital for ~Rs. 100 Cr. Ascent Capital will also infuse ~Rs. 50 Cr into Pivot Path for growth. This reclassifies Pivot Path as an associate.
Strides Pharma acquires and in-licenses multiple generic brands from Sandoz for an upfront consideration of approximately 99.6 Cr. This move strengthens Strides' Africa business, aiming for a top-five market position in Sub-Saharan Africa. The portfolio includes products with individual annual sales exceeding 8.3 Cr.
Strides Pharma's Board has strengthened its internal policy on handling price-sensitive company information. This update aims for prompt and uniform disclosure of important news, boosting transparency for investors. The Chief Financial Officer is now designated to manage all information dissemination, including responding to market rumors. The revised policy details how...
Strides Pharma Science announced an operational update for its wholly-owned UK subsidiary, Strides Arcolab International Limited (SAIL). The statutory auditor, MacIntyre Hudson LLP, has transitioned its audit responsibilities to MHA Audit Services LLP. This change resulted from MacIntyre Hudson LLP's internal restructuring, which separated its audit practice from non-audit services...